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Summary
Introduction:  Perioperative  blood  loss  is  a  frequent  cause  of  complications  in  total  hip  replace-
ment (THR).  The  present  prospective  study  assessed  the  efﬁcacy  of  tranexamic  acid  (Exacyl®)
in reducing  blood  loss  in  primary  THR  associated  to  rivaroxaban  (Xarelto®)  thromboprophylaxis.
Hypothesis:  Tranexamic  acid  associated  to  rivaroxaban  reduces  blood  loss.
Material  and  method:  A  prospective  case-control  study  included  70  primary  cementless  THRs
performed  by  a  single  surgeon  on  a  standardized  technique,  between  September  2009  and
September  2010.  Thirty-seven  patients  received  perioperative  tranexamic  acid;  all  patients
received  rivaroxaban  thromboprophylaxis.
Results:  There  was  no  signiﬁcant  difference  between  the  two  groups  in  terms  of  peroperative
blood-loss  volume  or  rates  of  thromboembolic  or  ischemic  events  or  hematoma.  Postopera-
tive blood  loss,  D0-5  differential  hemoglobinemia  and  real  blood  loss  (in  mL  100%  hematocrit)
were signiﬁcantly  lower  in  the  tranexamic  acid  group.  No  transfusions  were  required  in  the
tranexamic  acid  group,  versus  four  in  the  control  group.
Discussion:  Tranexamic  acid  associated  to  direct  anti-Xa  (antithrombin-independent)  oral  anti-
coagulants was  effective  in  reducing  postoperative  blood  loss,  improving  hemoglobinemia  at  5
days and  reducing  transfusion  rates.  The  results  also  conﬁrmed  the  efﬁcacy  of  and  tolerance
for rivaroxaban  thromboprophylaxis  in  primary  THR,  with  no  clinical  thrombotic  events  induced
by the  association  of  tranexamic  acid  with  rivaroxaban.
∗ Corresponding author. Tel.: +33 2 49 83 47 273, fax: +33 2 98 34 78 13.
E-mail address: arnaud.clave@chu-brest.fr (A. Clavé).
877-0568/$ – see front matter © 2012 Elsevier Masson SAS. All rights reserved.
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Conclusions:  Tranexamic  acid  is  a  simple  means  of  reducing  postoperative  blood  loss  in  THR,
without increased  risk  of  thromboembolism  when  associated  to  rivaroxaban  thromboprophy-
laxis.
Level of  evidence:  Level  III  prospective  case-control  study.
© 2012  Elsevier  Masson  SAS.  All  rights  reserved.
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Total  hip  replacement  (THR)  is  one  of  the  most  common
orthopedic  procedures,  with  more  than  100,000  primary
implantations  in  France  in  2001  [1].  Frequency  and  the  func-
tional  beneﬁt  testiﬁed  to  by  the  patients  have  made  it  so
popular  as  to  seem  sometimes  ‘‘banal’’.  However,  it  is  not
free  of  complications.  Postoperative  anemia,  while  often
considered  harmless,  is  in  fact  a  cause  of  serious  morbid-
ity  [2,3]: decompensation  of  chronic  ischemic  pathologies,
delayed  resumption  of  activity,  prolonged  rehabilitation
with  resultant  loss  of  independence,  reduced  quality  of  life
and  signiﬁcantly  increased  ﬁnancial  cost.
The  European  multi-center  OSTHEO  study  [4],  involving
225  hospitals  and  2640  primary  THR  patients,  quantiﬁed
perioperative  blood  loss  at  a  mean  1934  mL  total  blood,  or
one  third  of  blood  mass  in  certain  patients.  When  blood-
saving  techniques  (rhEPO,  scheduled  autologous  transfusion,
iron  supplementation,  isovolemic  preoperative  hemodilu-
tion,  blood  recycling,  antiﬁbrinolytics)  are  not  deployed,
80%  of  patients  may  require  transfusion.  While  it  must  not
be  forgotten  that  the  risks  associated  with  non-transfusion
far  outweigh  those  of  transfusion-related  accidents  [5,6],
shortage  of  blood  supplies  in  France  and  fear  (often  media-
induced)  of  homologous  transfusion  and  its  cost  justify  the
search  for  new  techniques  of  blood  saving  in  both  the  surgi-
cal  and  medical  areas.
We  undertook  a  prospective  assessment  of  the  effect  of
an  antiﬁbrinolytic,  tranexamic  acid  (Exacyl®),  on  perioper-
ative  blood  loss  in  primary  THR.  Although  this  application
is  not  novel  in  orthopedics  [7—9], it  is  not  widespread.
The  originality  of  the  study  lays  in  the  entire  cohort
receiving  postoperative  thromboprophylaxis  with  a  recently
marketed  oral  antiactivated-factor-X  (anti-Xa),  rivaroxaban
(Xarelto®),  intended  to  simplify  prevention  of  thromboem-
bolic  events  [10].
The  objective  of  study  was  to  assess  the  efﬁcacy  of
tranexamic  acid  in  reducing  blood  loss  during  primary
cementless  THR  with  associated  rivaroxaban  thrombopro-
phylaxis.
Material and method
Patients
The  origin  of  this  single-blind  prospective  case-control  study
lays  in  a  joint  decision  of  the  surgical  and  anesthesia  teams
to  implement  a  tranexamic  acid  protocol.  All  cases  of  pri-
mary  THR  for  osteoarthritis  of  the  hip  performed  by  a  single
surgeon  (J.L.)  between  September  2009  and  September  2010
were  included.
a
o
d
eExclusion  criteria  were:  contra-indications  for  tranex-
mic  acid  (chronic  ischemic  pathology,  history  of
hromboembolism,  renal  insufﬁciency)  or  for  rivarox-
ban  thromboprophylaxis  (severe  renal  insufﬁciency
clearance  <  30  mL/min)  or  Child  class  B  cirrhosis  of  the
iver  with  coagulopathy).
Seventy  patients  were  included  on  these  criteria,  divided
nto  two  groups  according  to  date  of  surgery:
group  A,  receiving  antiﬁbrinolytic  treatment  by  tranex-
amic  acid  (N  =  37),  operated  on  between  the  beginning  of
January  and  the  end  of  September  2010;
control  group  B,  without  tranexamic  acid  (N  =  33),  oper-
ated  on  between  the  beginning  of  September  and  the  end
of  December  2009.
No  patients  were  lost  to  follow-up  or  left  the  study;  all
ata  were  included  in  the  statistical  analysis  according  to
he  original  distribution  between  groups.
The  antiﬁbrinolytic  protocol,  recommended  by
osencher  et  al.  [5],  comprised  intravenous  (iv)  tranexamic
cid  administered  peroperatively  (at  incision):  1  g  iv;  and
ostoperatively:  1  gram  iv  at  H3,  H7  and  H12.
All  patients  had  an  anesthesia  consultation  at  least  1
onth  before  surgery.  In  a  blood-saving  strategy,  those  with
emoglobinemia  less  than  12  g/dL  received  an  injection  of
0,000  IU  rhEPO  (human  recombinant  erythropoietin).  Those
ith  hemoglobinemia  less  than  11  and  less  than  10  g/dL
n  the  day  of  consultation  received  respectively  two  and
hree  injections  (one  injection  per  week)  of  40,000  IU
hEPO  before  surgery  associated  to  oral  iron  supplementa-
ion  (200  mg/d)  up  to  the  surgery  day.  Antiplatelet  therapy
as  systematically  interrupted  5  days  before  surgery  and
esumed  on  postsurgical  day  1.
urgical  technique,  anticoagulants,  transfusion
olicy
ll  THRs  were  performed  by  a  single  experienced  surgeon
J.L.)  and  anesthesia  team,  under  spinal  anesthesia.  The
tandardized  procedure  used  a  minimally  invasive  poste-
ior  approach  and  cementless  implants:  CorailTM stem,  with
innacleTM alumina/alumina  cup  in  23  patients  of  group  A
nd  18  patients  of  group  B,  or  GyrosTM (Depuy,  Saint  Priest,
rance)  steel/polyethylene  dual  mobility  cup  in  patients
ver  75  years  of  age  (14  in  group  A,  15  in  group  B).  Postopera-
ive  drainage,  equally  standardized,  used  one  intra-articular
nd  one  subcutaneous  size-10  Redon  drains,  ﬁtted  at  the  end
f  the  operation.  Both  were  removed  once  the  more  pro-
uctive  was  draining  ≤  60  mL/24hr,  or  by  day  5  at  the  latest
xcept  in  case  of  particular  complications.
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All  patients  underwent  functional  rehabilitation  with
ne  of  the  department’s  physiotherapists,  with  transfer  to
heelchair  as  of  D1  and  resumption  of  walking  as  of  D2.
Preventive  oral  anticoagulant  therapy  using  rivaroxaban
Xarelto®)  1  tab  per  day  was  initiated  6  to  8  hours  postoper-
tively  for  30  days.
Transfusion  policy  followed  Société  Franc¸aise
’Anesthésie  Réanimation  (SFAR)  guidelines:  autolo-
ous  packed  red  blood  cell  (PRBC)  transfusion  in  case
f  hemoglobinemia  less  than  7  g/dL  in  patients  with  no
elevant  history,  8—9  g/dL  in  case  of  cardiovascular  history,
nd  10  g/dL  in  case  of  clinical  intolerance  for  lower  con-
entrations,  acute  coronary  insufﬁciency  or  proven  cardiac
nsufﬁciency.  Oral  iron  supplementation  was  initiated  at
1  or  D5  when  hemoglobinemia  was  less  than  10  g/dL.  All
atients  were  checked  up  at  3  months  postoperatively.
ssessment
he  following  data  were  systematically  collected:
 To  assess  intergroup  homogeneity:  age;  gender;  weight;
American  Society  of  Anesthesiologists  (ASA)  score  [11];
type  of  anesthesia;  surgery  time;  and  anticoagulant  ther-
apy  (Table  1).
 To  assess  tranexamic  acid  action:  per-  and  postopera-
tive  blood  effusion  volume;  real  blood  loss;  need  for
PRBC  transfusion;  hemoglobinemia  at  D0  (preoperative),
D1  and  D5;  and  complications:  hematoma,  thromboem-
bolic  or  ischemic  events,  and  known  adverse  side  effects
of  tranexamic  acid  (where  administered).  All  data  were
recorded  by  an  independent  investigator,  other  than  the
surgeon  or  the  anesthetist.
The  studies  of  hemorrhage  during  orthopedic  surgery
ublished  by  Rosencher  et  al.  [4,5]  showed  that  blood
oss  cannot  be  reduced  to  per-  and  postoperative  volumes,
hich,  in  addition  to  inherent  measurement  biases,  amount
o  no  more  than  two-thirds  of  real  blood  loss.
o
c
s
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Table  1  Patient  characteristics  in  the  two  groups.
A  -  Exacyl  
Number  of  operations  (=  patients)  37  
Male/female  12/25  
Mean age 69  (38;  84)  
ASA score I:  3.  II:  32.  III:2
Antiplatelets 6  
rhEPOa 6
Dual mobility  cup 14
Preventive  anticoagulation
Rivaroxaban  37  
Mean surgery  time  81  min  (50;  160
Complications
Peroperative  2  
Hematoma 0  
Clinical thromboembolic  0  
a All patients with hemoglobinemia < 11 g/dL at anesthesia consultatiA.  Clavé  et  al.
Real  blood  loss  was  therefore  calculated  from  the
tandard  formula:  Real  blood  loss  =  TBV  ×  (Ht  D0 —  Ht
5)  +  transfusion  volume.
The  result,  in  milliliters  of  100%  hematocrit,  represents
oss  of  red  blood  cells  rather  than  of  total  blood  (includ-
ng  plasma  and  other  formed  elements).  Total  blood  volume
TBV)  is  the  volume  of  circulating  blood:  i.e.,  body  weight
kg)  ×  65  mL/kg  for  women  and  70  mL/kg  for  men;  Ht  D0 is
he  preoperative  hematocrit  value,  and  Ht  D5 the  hemat-
crit  at  postoperative  day  5.  Transfusion  volume  was  150  mL
00%  blood  for  homologous  and  100  mL  for  autologous  trans-
usion.
tatistics
he  principle  assessment  criteria  were  real  blood  loss,  effu-
ion  volume  and  delta  hemoglobinemia  between  D0  and
5.  Statistical  analysis  used  StatplusTM software  (AnalystSoft
nc.,  Vancouver,  Canada).  Quantitative  variables  were  ana-
yzed  by  comparison  of  means  using  the  Student  t-test  (equal
ariances),  t-test  for  unequal  variances  and  Mann—Whitney
est  (independent  groups);  qualitative  variables  were  ana-
yzed  by  Fisher  test.  The  signiﬁcance  threshold  was  set  at
 <  0.05.
esults
tudy  population
roup  A  (tranexamic  acid)  comprised  37  patients:  25
omen,  12  men;  mean  age,  69  years  (Table  1).  Three
ere  graded  ASA  1,  32  ASA  2 and  two  ASA  3.  Six  were
eceiving  antiplatelet  therapy  (Kardegic® 75  mg  (acetylsal-
cylic  acid)).  Mean  surgery  time  was  81  min  (range,  50
o  120  min).  There  were  two  peroperative  complications:
ne  acetabular  fracture  requiring  autograft,  a  Kerboull
ross  plate  and  cementing  of  one  cup;  and  one  femoral
haft  crack  requiring  complementary  osteosynthesis  by  cer-
lage.  There  were  no  postoperative  complications,  although
B  -  Control  P
33
13/20  0.3603
73  (59;  86)  0.12
I:  2.  II:  28.  III:  3  0.52
6  0.5379
8  0.2948
15 0.3435
33
)  83  min  (65;  120)  0,94
0  0.2758
1  0.4714
0
on underwent preoperative rhEPO injection.
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Table  2  Peroperative  blood  effusion  volume.
Group  A:  Exacyl  Group  B:  Control
n  37  33
Mean blood  loss  (mL)  227.027  228.7878
Range (mL)  60—220  60—500
95% conﬁdence  interval  185.4994—268.5546  188.3213—269.2543
Variance 16610.3603  14067.2348
Standard deviation  (of  mean) 21.1879 20.6465
F-test  for  equal  variances P  =  0.6367
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echo-Doppler  was  needed  to  rule  out  two  clinically
suspected  deep  venous  thromboses.  Redon  drains  were
removed  at  D2,  D3  and  D4  for  respectively  9,  17  and
11  patients.  Two  patients  exhibited  nausea  at  the  second
administration  of  tranexamic  acid;  this  was  dealt  with  as
an  adverse  side  effect,  leading  to  termination  of  treat-
ment.
Control  group  B  comprised  33  patients:  20  women,  13
men;  mean  age,  73  years  (Table  1).  Two  were  graded
ASA  1,  28  ASA  2  and  three  ASA  3.  Six  were  receiv-
ing  antiplatelet  therapy  (Kardegic® 75  mg  [acetylsalicylic
acid]).  Mean  surgery  time  was  83  min  (range,  65  to  120  min).
There  were  no  peroperative  complications.  Redon  drains
were  removed  at  D2,  D3,  D4  and  D5  for  respectively  six,
13,  12  and  two  patients.
In  both  groups,  thromboprophylaxis  used  Xarelto® alone.
Antiplatelet  therapy  was  systematically  interrupted  5  days
before  surgery  and  resumed  at  postoperative  day  1.  No
thromboembolic  complications  were  observed  at  discharge
or  3-months  follow-up.
Assessment  of  blood  loss
Mean  peroperative  bleeding  was  227  mL  and  229  mL  in
groups  A  and  B,  respectively:  i.e.,  no  signiﬁcant  differ-
ence  (P  =  0.9529)  (Table  2).  Mean  postoperative  bleeding  was
440.5  mL  and  641.8  mL  in  groups  A  and  B,  respectively:  this
209  mL  difference  was  statistically  signiﬁcant  (P  =  0.0002)
(Table  3).
t
a
m
T
Table  3  Postoperative  blood  loss.
Group  A
n  37  
Mean blood  loss  (mL)  440.540
Range (mL)  160—780
95% conﬁdence  interval  395.630
Variance 19426.0
Standard deviation  (of  mean)  22.9135
F-test for  equal  variances  
Welch test  (unequal  variances)  
Mann—Whitney  (independent  groups)  P  =  0.9529
nalysis  of  hemoglobinemia  variation  between  D0,
1 and  D5
ean  hemoglobinemia  at  D0  was  14.15  g/dL  in  group  A,
nd  14.14  g/dL  in  group  B  (P  =  0.47);  at  D1,  11.41  g/dL  vs.
0.51  g/dL  (P  =  0.002);  and  at  D5,11.05  g/dL  vs.  10.24  g/dL
P  =  0.002)  (Table  4).  Mean  D0—D5  difference  was  3.1  g/dL
range,  1.5  to  5  g/dL)  in  group  A  and  3.893  g/dL  (range,  1
o  6  g/dL)  in  group  B:  this  0.796  g/dL  difference  in  favor  of
roup  A  was  statistically  signiﬁcant  (P  =  0.001)  (Table  5).
Maximum  difference  in  hemoglobinemia  with  respect  to
0  was  3.156  g/dL  (range,  1.5  à  4.8  g/dL)  in  group  A  and
.130  g/dL  in  group  B  (range,  1.5  to  6  g/dL):  this  0.965  g/dL
ifference  in  favor  of  group  A was  statistically  signiﬁcant
P  =  0.0001)  (Table  6).
nalysis  and  management  of  real  blood  loss
n  group  A,  mean  real  blood  loss  in  mL  100%  hematocrit  was
14.63,  versus  587.63  mL  in  group  B  (Table  7):  this  173  mL
ifference  was  statistically  signiﬁcant  (P  =  0.0006).
In  group  A,  no  PRBC  transfusions  were  required.  Four
atients  received  oral  iron  and  folic  acid  supplementation.
n  group  B,  there  were  four  transfusions:  one  immediate
ostoperative  autologous  transfusion  of  one  unit  PRBC,  and
hree  homologous  transfusions  of  two  units  at  D2,  two  units
t  D2,  D6  and  D10,  and  two  units  at  D6,  due  to  hemoglobine-
ia  at  the  lower  limit  or  poor  clinical  tolerance.
hese  results,  however,  showed  no  statistically  signiﬁcant
:  Exacyl  Group  B:  Control
33
5  641.8181
 100—1300
8—485.4502  547.6255—736.0107
885  76216.9034
 48.0583
P  =  0.0001
P  =  0.0002
P  =  0.0012
488  A.  Clavé  et  al.
Table  4  Mean  hemoglobinemia:  D0,  D1  and  D5.
Group  A:  Exacyl  Group  B:  Control  P
D0
Mean  Hb  (g/dL)  14.15  14.14  0.471
Range 12.8—16.2  12.2—16.1
95% conﬁdence  interval  13.8—14.5  13.84—14.47
Variance 1.1587  0.9362
D1
Mean Hb  (g/dL) 11.41  10.51  0.002
Range 9.4—13.9  7.6—13.5
95% conﬁdence  interval 11.04—11.8  10—11
Variance 1.3354 2.0465
D5
Mean Hb  (g/dL)  11.05  10.24  0.002
Range 8.8—13.1  7.6—12.4
95% conﬁdence  interval  10.69—11.42  9.85—10.63
Variance 1.2721  1.2594
Table  5  Statistical  analysis  of  difference  in  mean  hemoglobinemia  between  D0  and  D5.
n  Mean  95%  CI  SD  Median
Group  A:  Exacyl  37  —3.097  —3.644  to  —2.83  0.828  —3
Group B:  Control  33  —3.893  —4.291  to  —3.496  1.165  —4.2
 g/dL —0.796
F-test  for  equal  variances  0.048
t-test  for  unequal  variances P  =  0.001
Mann—Whitney  (independent  groups)  P  =  0.0025
Table  6  Statistical  analysis  of  maximum  difference  in  hemoglobinemia  with  respect  to  D0.
N Mean 95%  CI SD Median
Group  A:  Exacyl 37 —3.156  —3.443  to  —2.87  0.888  —3.000
Group B:  control 33  —4.130  —4.508  to  —3.752  1.108  —4.300
 g/dL  —0.9656
F-test  for  equal  variances 0.1998
Student  t-test  P  =  0.0001
Table  7  Analysis  of  real  blood  loss.
Group  A:  Exacyl  Group  B:  Control
n  37  33
Mean blood  loss  (mL)  414.63  587.63
Range (mL)  204.8—842.8  158—1428.75
95% conﬁdence  interval  367.03—462.24  507.28—668
Variance 21240.44718  53789.5886
Difference (in  mL)  —173  mL
F-test for  equal  variances  P  =  0.0074
t-test for  unequal  variances  P  =  0.0006
Mann—Whitney  (independent  groups)  P  =  0.00015
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Table  8  Cost/effectiveness  ratio  for  the  various  blood-saving  strategies  according  to  Zufferey  et  al.  [27].
Technique  Studies  Reduction  in
PRBC
transfusions
DVT  Price
Scheduled  autologous
transfusion  [26]
3  RR:  0.16
(0.07—0.36)
RR:  0.82
(0.21—3.13)
615  Euros
2 units
EPO [24]  3  RR:  0.50
(0.39—0.64)
RR  not
assessed
NS
(P =  0.14)
1459  Euros
4  injections
Cell Saver  [25]  11  RR:  0.35
(0.24—0.52)
RR:  0.93
(0.31—2.77)
100  Euros
Machine
excluded
Tranexamic [27]  20  RR:  0.42
(0.32
RR:  0.96 2  Euros
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ddifference  in  transfusion  rates  (P  =  0.112).  Nine  patients  in
group  B  received  oral  iron  and  folic  acid  supplementation.
Discussion
To  the  best  of  our  knowledge,  this  is  the  ﬁrst  prospective
study  of  the  effect  of  tranexamic  acid  associated  to  a  new
generation  oral  anticoagulant  in  primary  total  hip  replace-
ment.  One  gram  iv  Exacyl® at  incision  then  postoperatively
at  H3,  H7  and  H12  signiﬁcantly  reduced  blood  loss  without
increasing  the  risk  of  clinically  symptomatic  thromboem-
bolic  events  in  primary  cementless  THR  with  rivaroxaban
thromboprophylaxis.  There  was  a  signiﬁcant  beneﬁt  in  the
tranexamic  acid  group  in  terms  of  postoperative  bleeding
(440  ml  vs.  642  mL)  and  blood  loss  in  mL  100%  hematocrit
(corresponding  to  real  erythrocyte  loss)  (414.6  vs.  587.6).  In
contrast,  there  was  no  signiﬁcant  difference  in  peroperative
effusion  (227  mL  vs.  229  mL).
The  theoretical  risk  with  a  lysine-analog  antiﬁbrinolytic
such  as  tranexamic  acid  is  thrombosis  [5,12]. The  present
study  found  no  deep  venous  thrombosis  or  clinically  symp-
tomatic  pulmonary  embolism  during  hospital  stay  or  at
3  months  follow-up.  However,  given  this  lack  of  sugges-
tive  clinical  signs,  no  imaging  was  prescribed  which  might
have  shown  up  infraclinical  venous  thrombosis,  except  in
two  group-A  patients  in  whom  echo-Doppler  ruled  out
this  diagnosis.  The  study  design  excluded  patients  at  risk
of  thromboembolic  or  ischemic  complications,  and  only
low-risk  patients  underwent  the  concomitant  oral  anti-Xa
thromboprophylaxis.  This  introduced  a  systematic  under-
estimation  of  thromboembolic  risk  by  excluding  high-risk
cases,  which  is  an  important  study  limitation.  There  were
only  two  minor  adverse  effects  (nausea)  implicating  tranex-
amic  acid  treatment,  which  was  terminated  after  the  second
injection.
This  prospective  diagnostic  study  could  not  be  random-
ized  or  performed  under  double-blind.  Patients  signed  no
particular  consent  form  and  no  ethics  committee  or  EudraCT
(European  Union  Drug  Regulating  Authorities  Clinical  Trials)
registration  was  made.  Several  factors,  however,  limited
the  risk  of  ﬁrst  or  second  order  bias:  good  intergroup
p
e
[
a—0.55) (0.66—1.40) 2  g
omogeneity,  single-center  single-operator  management,
nd  data  collection  by  an  investigator  independent  of  the
urgeon.  The  short  period  required  for  data  harvesting
voided  any  follow-up  bias,  as  no  patients  were  lost  to
ollow-up;  it  was  still  possible  for  the  data  of  the  two
atients  who  did  not  receive  the  entire  tranexamic  acid
reatment  due  to  an  adverse  effect  to  be  taken  into  account
or  their  original  group.
Blood-loss  assessment  in  terms  of  effusion  volume  was
aintained  in  the  study  out  of  ‘‘surgical  habit’’  and  to
llow  comparison  with  previous  studies  and  current  prac-
ice.  But,  it  is  probably  the  worst  way  of  making  assessment
nd  comparison,  despite  being  still  very  common  [13]. Rigor-
us  reproducible  measurement  of  effusion  volume  is  difﬁcult
nd  subject  to  strong  observer  bias,  and  the  method  fails
o  take  account  of  blood  loss  by  extraversion  or  hematoma
ormation,  which  may  in  fact  represent  up  to  one  third  of
leeding  [13]. The  method  should  no  longer  be  used  for
uantifying  blood  loss,  and  we  prefer  to  calculate  red  blood-
ell  loss,  a  true  measure  of  blood  loss  which  we  refer  to  as
‘real  blood  loss’’.  The  study  did  not  take  account  of  effects
ue  to  anesthetic  substances  and  ﬁlling  ﬂuids  [14]; anes-
hesia,  however,  was  performed  by  a  single  team  for  all  70
atients,  so  that  its  impact  can  be  assumed  to  have  been
omogeneous.
The  present  results  conﬁrm  the  literature  data  on  the
fﬁcacy  of  tranexamic  acid  in  reducing  postoperative  blood
oss,  improving  D5  hemoglobinemia  and  reducing  resort  to
ransfusion  [15—20]. Recent  studies,  including  several  meta-
nalyses,  further  reported  improvement  in  peroperative
ffusion,  not  conﬁrmed  by  the  present  study  [18,19,21—23].
A  literature  search,  however,  retrieves  studies  that  are
ard  to  compare  [18,23—25].  Populations  are  not  match-
ble,  and  surgical  management  varies  widely  (indications,
pproach,  type  of  implant,  blood-saving  strategy,  anesthesia
anagement,  tranexamic  acid  injection  schedule),  as  does
hromboembolism  risk  prevention.  Studies  are  rarely  ran-
omized  with  double  blind,  and  series  are  often  less  than  50
atients.  The  present  study  highlights  the  efﬁcacy  of  and  tol-
rance  for  rivaroxaban  thromboprophylaxis  in  primary  THR
10],  without  clinical  thrombotic  events  when  tranexamic
cid  is  associated  [17,21,26,27].
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The  study  conﬁrms  the  efﬁcacy  of  tranexamic  acid  in
educing  blood  loss  in  primary  THR  without  elevated  throm-
oembolic  risk  if  contra-indications  are  observed.  It  further
emonstrated  that  such  efﬁcacy  and  safety  persisted  when
ssociated  to  thromboprophylaxis  by  rivaroxaban,  the  ease
f  use  of  which  will  probably  lead  to  it  replacing  classical
eparin-type  anticoagulants  in  the  years  to  come.  Moreover,
n  this  period  of  budgetary  restrictions,  the  cost  of  tranex-
mic  acid  (2  Euros  for  2  g)  compared  to  classic  methods
19,25—27]  is  a  convincing  argument,  especially  as  Zufferey
t  al.  [20]  clearly  showed  the  cost/beneﬁt  ratio  (Table  8).
A  prospective  double-blind  study  of  time  to  resumption
f  walking,  hospital  stay  and  resultant  costs  could  provide
 quantitative  basis  to  the  role  of  tranexamic  acid  in  hip
mplant  surgery.  The  present  results  encourage  us  to  exam-
ne  the  use  of  tranexamic  acid  in  THR  revision,  the  frequency
f  which,  with  the  associated  elevated  hemorrhage  risk,  is
iable  to  increase  following  demographic  trends  in  France.
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